University of Nantes
Multiple myeloma, Internal medicine, Surgery, Oncology and Bortezomib are his primary areas of study. His study in Multiple myeloma is interdisciplinary in nature, drawing from both Dexamethasone and Transplantation. His Internal medicine research incorporates elements of Gastroenterology and Pathology.
In his research on the topic of Surgery, Placebo is strongly related with Ixazomib. His research in Oncology intersects with topics in Survival analysis, Retrospective cohort study, Minimal Residual Disease Negativity and Daratumumab. His Carfilzomib study in the realm of Bortezomib connects with subjects such as Peripheral neuropathy.
The scientist’s investigation covers issues in Multiple myeloma, Internal medicine, Oncology, Surgery and Transplantation. His research on Multiple myeloma often connects related areas such as Dexamethasone. His Dexamethasone research is multidisciplinary, incorporating elements of Placebo and Adverse effect.
Philippe Moreau combines topics linked to Gastroenterology with his work on Internal medicine. His work investigates the relationship between Oncology and topics such as Immunology that intersect with problems in Cancer research. His Transplantation study combines topics in areas such as Maintenance therapy, Stem cell, Fludarabine and Cumulative incidence.
His main research concerns Multiple myeloma, Internal medicine, Oncology, Dexamethasone and Lenalidomide. His studies in Multiple myeloma integrate themes in fields like Cancer research, Clinical trial, Refractory and Transplantation. His Internal medicine study often links to related topics such as Gastroenterology.
Philippe Moreau has included themes like Proteasome inhibitor, Regimen and Ixazomib in his Oncology study. Within one scientific family, he focuses on topics pertaining to Progression-free survival under Dexamethasone, and may sometimes address concerns connected to Melphalan. His studies deal with areas such as Thalidomide, Survival rate, Newly diagnosed, Minimal residual disease and Clinical endpoint as well as Lenalidomide.
Philippe Moreau spends much of his time researching Multiple myeloma, Internal medicine, Lenalidomide, Clinical trial and Bortezomib. His study in Multiple myeloma is interdisciplinary in nature, drawing from both Cancer research, Refractory, Transplantation and Intensive care medicine. His work deals with themes such as Maintenance therapy, Thalidomide and Regimen, which intersect with Transplantation.
He has researched Internal medicine in several fields, including Gastroenterology and Oncology. The various areas that he examines in his Lenalidomide study include Survival rate and Minimal residual disease. Philippe Moreau works mostly in the field of Bortezomib, limiting it down to topics relating to Standard treatment and, in certain cases, Discontinuation and Heart failure, as a part of the same area of interest.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel.
The New England Journal of Medicine (2016)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal;Valerie Lauwers-Cances;Gerald Marit;Denis Caillot.
The New England Journal of Medicine (2012)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau;Halyna Pylypenko;Sebastian Grosicki;Ievgenii Karamanesht.
Lancet Oncology (2011)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Philippe Moreau;Tamás Masszi;Norbert Grzasko;Nizar J Bahlis.
The New England Journal of Medicine (2016)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac.
Lancet Oncology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: